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The predictive values of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) gene expressions were
retrospectively evaluated in patients with gastric cancer treated by a regimen containing S-1. The study population consisted of 53
patients registered into different two phase II studies for metastatic gastric cancer; 27 patients treated by S-1-alone study: 26 patients
treated with S-1 combined with irinotecan (CPT-11). TS and DPD gene expressions in primary tumours were measured by the real-
time reverse transcription PCR method. There was no statistical difference in DPD gene expression in terms of response in cases
treated with S-1 alone and those treated with S-1 plus CPT-11. TS mRNA of responding tumours was lower than that of
nonresponding ones when treated with S-1 (Po0.005). In the S-1-alone group, taking TS cutoff as the median values, the response
rate in the low TS group was 50%, but only 8% in the high TS group (Po0.05). Patients with low TS gene expression survived longer
than those with high TS gene expression (Po0.0001). However, there was no statistically significant difference in response rate and
survival between patients with low TS tumours and those with high TS tumours, when the cutoff was taken as the median value of TS
gene expression in the group treated with S-1 plus CPT-11. In conclusion, treatment effects of S-1 monotherapy for gastric cancer
were determined by the status of TS gene expression, regardless of DPD gene expression. TS predictive power was overcome by
CPT-11 combination therapy with S-1.
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The main mode of action of 5-fluorouracil (5-FU) is thought to be
through its active metabolite, 5-fluoro-deoxyuridine-monopho-
sphate (FdUMP), which suppresses thymidylate synthase (TS), an
essential DNA synthetic enzyme that catalyses the methylation of
deoxyuridine monophosphate (dUMP) to deoxythymidine mono-
phosphate (dTMP) (Langenbach et al, 1972; Peters et al, 1995). 5-
FU is catabolised to 2-fluoro-b-alanine by dihydropyrimidine
dehydrogenase (DPD), the first and rate-limiting enzyme (Heggie
et al, 1987).
S-1 is a new oral fluorinated pyrimidine, in which tegafur (FT)
has been combined with two 5-FU modulating substances: 5-
chloro-2,4-dihydroxypyrimidine (gimeracil, CDHP), and potas-
sium oxonate (oteracil potassium, Oxo), in a molar ratio of FT:
CDHP: Oxo¼1:0.4:1 (Shirasaka et al, 1996). FT is a prodrug of 5-
fluorouracil (FU), which is absorbed after oral ingestion followed
by conversion to 5-FU. CDHP reversibly inhibits the activity of
DPD (Yamada et al, 2003), resulting in the increase of antitumour
activity (Tatsumi et al, 1987). Two phase II studies of S-1 showed
activity in gastric cancer, accompanied by mild-to-moderate
toxicity. The response rate was 44–49% and the median survival
time was 207–250 days, with 1- and 2-year survival rates of 36–37
and 14%, respectively (Sakata et al, 1998; Koizumi et al, 2000).
Irinotecan hydrochloride (CPT-11) is a water-soluble, semisyn-
thetic derivative of camptothecin (CPT) that retains the original
antitumour effects of CPT-11 due to the inhibition of DNA
topoisomerase I (Topo-I) (Hsiang et al, 1989). CPT-11 was shown
to lack cross-resistance with fluoropyrimidines in both experi-
mental models and the clinical setting (Vanhoefer et al, 2001). The
response rate of CPT-11 alone in gastric cancer was 23% in a
Japanese phase II study (Futatsuki et al, 1994). The response rate
in patients with prior 5-FU-containing regimens was 18.9%, which
indicated a lack of cross-resistance between CPT-11 and 5-FU in
gastric cancer. In our previous phase I study of S-1 and CPT-11 for
metastatic gastric cancer, the recommended dose was 80mgm
 2 of
CPT-11 on days 1 and 8 and 80mgm
 2day
 1 (40mgm
–2b.i.d.) of S-1
for the first 2 weeks, repeated every 4 weeks (Yamashita et al, 2003).
In colorectal cancer, both intratumoural TS and DPD gene
expression have been indicated to be positive predictive markers
for the effectiveness of 5-FU or UFT combined with leucovorin
(Salonga et al, 2000; Ichikawa et al, 2003). However, there is little
information about the predictive values of TS or DPD gene
expression in treatment with S-1-containing regimens. In this pilot
study, we evaluated the predictive values of TS and DPD gene
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lexpressions in cases of metastatic gastric cancer treated with S-1
or S-1 combined with CPT-11, using formalin-fixed, paraffin-
embedded tumour specimens.
PATIENTS AND METHODS
Clinical methods
The study population consisted of 53 patients with metastatic
gastric cancer who received chemotherapy for metastatic disease
after resection of primary tumours at the Second Department of
Surgery, Saitama Medical School. All 53 patients were registered
for two independent phase II studies; 27 patients for the phase II
study of S-1 alone from January 1999 to March 2000, and 26
patients for the phase II study of S-1 combined with CPT-11 from
January 2001 to December 2002.
In both phase II studies, no patients had received 5-FU
chemotherapy preoperatively. Eligible patients for two phase II
studies had (a) histologically proven gastric cancer with at least
one measurable metastatic lesion; (b) Eastern Clinical Oncology
Group scale performance status of 2 or better (Zubrod et al, 1960);
(c) age of 80 years or younger; (d) no prior chemotherapy
regimens for metastatic disease before entry; (e) adequate
haematological, hepatic, and renal function; and (f) life expectancy
of over 3 months. In patients treated with adjuvant chemotherapy,
there was a washout period of at least 4 weeks. Patient
characteristics are listed in Table 1.
Before the treatment and after every two cycles of treatment,
measurable disease was reassessed by computed tomography.
Response evaluation was based on the standard UICC guidelines as
complete response (CR), partial response (PR), no change (NC), or
progressive disease (PD) (Hayward et al, 1978). There were one
CR, seven PR, 13 NC, and six PD with a 29.6% (eight out of 27)
response rate in the S-1-alone regimen (95% confidence interval,
13.8–50.2%), and two CR, 11 PR, nine NC, and four PD with a
50.0% (13 out of 26) response rate in the S-1 combined with CPT-
11 regimen (95% confidence interval, 29.9–70.1%). All patients
eventually died from cancer. The median survival times were 6.3
months, ranging from 2.1 to 23.0 months and 6.3 months ranging
from 2.8 to 26.6 months for patients treated with S-1 and S-1
combined with CPT-11, respectively.
The S-1-alone regimen consisted of oral administration of S-1
(Taiho Pharmaceutical Co., Ltd., Tokyo, Japan) at 80mgm
 2
(standard dose) daily (40mgm
 2 b.i.d.) after meals. Three doses of
S-1 were established according to body surface area (BSA) as
follows: BSA o1.25m
2; 80mgday
 1; 1.25m
2pBSA o1.5m
2,
100mgday
 1; and 1.5m
2 pBSA, 120mgday
 1, as described
previously (Sakata et al, 1998; Koizumi et al, 2000). One course
consisted of consecutive administration for 28 days followed by 14
days of no drug administration.
The S-1 combined with CPT-11 comprised oral administration
of S-1 at 80mgm
 2day
 1 (40mgm
 2 b.i.d.) during 2 weeks, with a
90-min infusion of 80mgm
 2day
 1 CPT-11 at days 1 and 8. Cycles
were repeated every 4 weeks. Dose calculation of S-1 was
performed in the same way as in the S-1-alone regimen. This
regimen was decided according to previously reported phase I
study (Yamashita et al, 2003).
These studies were approved by the Institutional Review Board
of Saitama Medical School, and all patients gave written informed
consent.
Laboratory methods
Microdissection in primary tumours A representative formalin-
fixed, paraffin-embedded (FFPE) tumour specimen obtained from
primary tumours was selected by a pathologist (MS) after
examination of the haematoxylin- and eosin-stained slides.
Sections 10mm in thickness were stained with nuclear Fast Red
to enable visualisation of histology for laser capture microdissec-
tion (PALM Microlaser Technologies AG, Munich, Germany),
which was performed to ensure that only tumour cells were
studied. Microdissected samples were collected into a microcen-
trifuge tube.
RNA extraction and cDNA synthesis RNA extraction and cDNA
synthesis were done in Response Genetics Inc. (Los Angeles, CA,
USA). RNA extraction was performed according to a proprietary
procedure (US patent number 6,248,535) (Lord et al, 2000;
Kornmann et al, 2003). Briefly, 600ml of xylene was added to each
tube. After centrifugation for 7min at 14000r.p.m., the super-
natant was discarded, and the washing step was repeated three
times. The deparaffinised materials were rehydrated in xyle-
ne:ethanol:water at the following ratios (95:95:5, 95:90:10,
95:80:20; 95:75:25, and 95:70:30). After each step, the
rehydration medium was removed after centrifugation for 7min
at 14000r.p.m. After discarding the last supernatant, the pelleted
sections were resolved in 70% ethanol. Then 400ml of buffer (4 M
guanidine isothiocyanate solution including 0.5% sarcosine and
8ml1 M DTT) were added to the dried tissue and homogenised
mechanically. For RNA demodification, homogenates were heated
at 951C for 30min. RNA was extracted from homogenates by
addition of 50mlo f2 M sodium acetate (pH 4.0), 500ml of water-
saturated phenol, and 100ml of chloroform–isoamyl mixture
(49:1). RNA was recovered from the water phase by isopropanol
precipitation and transferred to a new tube and precipitated with
10ml glycogen and 400ml isopropanol for 30min at  201C. After
centrifuging for 7min at 14000r.p.m., the pellet was washed with
500ml 75% ethanol. After drying, the pellet was dissolved in 50ml
5m M Tris-HCl (pH 8.0). Reverse transcription was carried at 391C
for 45min using 400U of MMLV reverse transcriptase, 1  first
strand buffer, 0.04mgml
 1 random hexamers, 10mM DTT, and
1m M deoxynucleoside triphosphate.
Table 1 Patient characteristics
S-1 alone S-1 plus CPT-11
No. of patients 27 26
Age (years)
Median 58 61
Range 29–78 34–80
Gender
Male/female 20/7 19/7
PS
0/1/2 19/5/3 20/5/1
Histology
Intestinal/diffuse 10/17 11/15
Metastasis
Synchronous/metachronous 10/17 12/14
Adjuvant chemotherapy
Yes/no 14/13 12/14
Metastatic site
Liver 8 8
Lymph node 15 17
Lung 5 3
Others 5 8
Second-line chemotherapy
Taxanes 5 10
Cisplatin+CPT-11 2 0
CPT-11 3 0
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were amplified by quantitative PCR using a fluorescence-based
real-time detection method (ABI PRISM 7900 Sequence Detection
System (Taqman); Applied Biosystems, Foster City, CA, USA) as
previously described (Kornmann et al, 2003). Polymerase chain
reaction was carried out for each gene of interest, and b-actin was
used as an internal reference gene. The 25ml PCR reaction mixture
contained 600nmoll
 1 of each primer, 200nmoll
 1 each of dATP,
dCTP, and dGTP, 400mmoll
 1 dUTP, 5.5mmoll
 1 MgCl2, and 1 
TaqMan buffer A containing a reference dye (all reagents were
supplied by Applied Biosystems). The primers and probe
sequences used were as follows: TS primers: GCCTCGGTG-
TGCCTTTCA and CCCGTGATGTGCGCAAT, probe 6FAM
(carboxyfluorescein)-50-TCGCCAGCTACGCCCTGCTCA-30TAMRA
(N,N,N0,N0-tetramethyl-6carboxyrhodamine); DPD primers: AG-
GACGCAAGGAGGGTTTG and GTCCGCCGAGTCCTTACTGA,
probe 6FAM-50- CAGTGCCTACAGTCTCGAGTCTGCCAGTG -
30TAMRA; b-actin primers: TGAGCGCGGCTACAGCTT and
TCCTTAATGTCACGCACGATTT, probe 6FAM-50- ACCAC-
CACGGCCGAGCGG -30TAMRA. The PCR conditions were 501C
for 10s and 951C for 10min, followed by 42 cycles at 951C for 15s
and 601C for 1min. Relative gene expression of TS and DPD was
determined based on the threshold cycles of each gene in relation
to the threshold cycle of the corresponding internal standard b-
actin. The rise of the b-actin signal after cycle 37 using the
described conditions indicated an insufficient amount of mRNA
present for the subsequent TS and DPD quantitation.
The studies to validate these methods have been previously
reported in colorectal cancer tissues (Kornmann et al, 2003). TS
mRNA levels of paraffin-embedded material after complete
pathological examination closely correlated with those of corre-
sponding fresh-frozen tumour specimens obtained during surgery
(r¼0.70), although TS mRNA levels were Bthree-fold lower in
paraffin-embedded tissues than in fresh-frozen tissues.
Statistics Statistical analysis was performed using JMP software
version 5.01 (SAS Institute, Inc., Cary, NC, USA). The Mann–
Whitney U test was used to compare the responders and
nonresponders in terms of the related gene expression. To evaluate
the association with response, two-sided Fisher’s exact test was
used. Survival was calculated from the onset of chemotherapy until
death. The overall survival curve was calculated using the Kaplan–
Meier method, and differences were assessed by the log-rank test.
A P-value of less than 0.05 was taken to indicate a statistically
significant difference.
RESULTS
Both relative TS and DPD mRNA expressions were determined by
the fluorescence-based real-time detection method in specimens
from all 53 patients with obtained the primary gastric cancer.
Tumours were categorised as either responding or not responding
to each regimen.
In the S-1-alone regimen, the median values of DPD mRNA
expressions were 1.22 (range: 0.84–2.16) and 0.99 (range: 0.42–
6.93) for responding tumours and nonresponding tumours,
respectively, without a statistically significant difference
(P¼0.41; Mann–Whitney U test; Figure 1). In contrast, the
median value of TS mRNA expression in responding tumours was
1.58 (range: 0.85–2.66). It was significantly lower than the 2.88
value (range: 1.06–13.37) in nonresponding cases (Po0.005;
Mann–Whitney U test; Figure 1).
The median value of TS in patients treated with the S-1-alone
regimen was 2.61 (range: 0.85–13.37), which was selected for a
cutoff value to separate high and low gene expression of TS. In
patients treated with S-1 alone, response rates were 50% (seven out
of 14) and 8% (one out of 13) in low (TS p2.61) and high TS (TS
42.61) tumours, respectively (Po0.05; two-sided Fisher’s exact
test) (Table 2). Patients with low TS gene expression survived
longer than those with high TS gene expression, with statistical
significance (median: 9.3 months ranging from 3.2 to 23.0 months
for patients with low TS gene expression tumours vs 4.0 months
ranging from 2.1 to 8.6 months for patients with high TS gene
expression tumour, Po0.0001; log-rank test; Figure 2).
In the S-1 combined with CPT-11 group, DPD mRNA
expressions showed no statistical difference between responding
(median 0.97, ranging from 0.48 to 2.12) and nonresponding
tumours (median 1.34, ranging from 0.64 to 3.16) (P¼0.10;
Mann– Whitney U test; Figure 3). Median values of TS mRNA
expression in responding and nonresponding tumours were 4.26
(range: 1.13–8.54) and 2.11 (range: 1.04–3.77), respectively
(P¼0.055; Mann–Whitney U test; Figure 3).
The median value of TS in patients treated with the S-1
combined with CPT-11 regimen was 2.54 (range: 1.04–8.54), which
was selected for a cutoff value to separate high and low gene
expression of TS. The response rates were 38% (five out of 13) and
62% (eight out of 13) in tumours with low (TS p2.54) and high TS
(TS 42.54) gene expression, respectively, with no statistical
significance (P¼0.43; two-sided Fisher’s exact test) (Table 2).
The median survival times were 6.6 months ranging from 2.8 to
16.0 months and 6.3 months ranging from 2.8 to 26.6 months for
patients with low TS gene expression tumour and those with high
TS ones, respectively, without statistical significance (P¼0.507;
log-rank test; Figure 4).
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Figure 1 DPD and TS mRNA in 27 primary gastric cancer treated with
S-1 alone in relation to nonresponse or response. There was no statistical
difference in DPD gene expression among responding and nonresponding
tumours. Median values of TS mRNA were 1.58 and 2.88 for responding
tumours and nonresponding tumours, respectively (Mann–Whitney U test;
Po0.005).
Table 2 Summary of response for tumours according to TS gene
expression in patients treated with S-1 alone or S-1 combined with CPT-11
TSp2.61 TS42.61
S-1 alone
No. of responding patients 7 1
No. of nonresponding patients 7 12
P-value o0.05
TS p2.54 TS 42.54
S-1 plus CPT-11
No. of responding patients 5 8
No. of nonresponding patients 8 5
P-value 0.43
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lDISCUSSION
In this study, we demonstrated that high TS gene expression in
primary gastric cancer predicted poor response in metastatic
tumour, with shorter survival, when treated with S-1 alone. When
CPT-11 was combined with S-1, intratumour TS gene expression
had no predictive values in terms of tumour shrinkage and
survival. Our data also demonstrated that the antitumour effect of
S-1 for gastric cancer was not influenced by intratumour DPD gene
expression, with or without combination with CPT-11.
TS expression in a primary gastric cancer had correlated with
the response of the primary tumour or metastatic tumour and
survival when treated by 5-FU containing regimen (Lenz et al,
1995; Boku et al, 1998; Yeh et al, 1998). As in previous reports,
tumours with low TS gene expression also had better response, and
longer survival than those with high TS gene expression when
treated with S-1 alone. (Figures 1 and 2).
However, experiments using human gastric cancer xenografts
indicated that there was no correlations between the antitumour
effect of S-1 and TS enzymatic activity and that an enhanced
blockade of RNA function attributed to the cytotoxicity of S-1 in
the addition of an increased inhibition of DNA (Fujiwara et al,
2003). S-1 showed antitumour effects in terms of response and
survival, regardless of the expression status of TS, when TS
expression was evaluated by immunohistochemical method using
antirecombinant human TS polyclonal antibody (Miyamoto et al,
2000). These findings did not agree with our results. The reason for
this disagreement among results remains unclear. The discrepancy
could therefore be due to the xenograft model, in which S-1 was
administered orally at doses of 10mgkg
 1. Another possible
explanation might be the difference in methodology for measuring
TS expression, because the fluorescence-based real-time detection
method is a more quantitative and objective evaluation method
than the immunohistochemical method (Kornmann et al, 2003).
When treated with S-1 combined with CPT-11, TS gene
expression does not predict the antitumour effect (Table 2). In
the CPT-11 combined with S-1 group, responding tumours had a
nonstatistically significant tendency towards higher TS gene
expression, compared with nonresponding ones (Figure 3). These
data suggested that tumours with a high expression of TS might
respond to additional CPT-11, whereas those tumours were
refractory to S-1 alone.
While the gene expression of Topo-I was reported to predict
tumour response to camptothecin derivative in cell cultures
(McLeod and Keith, 1996), clinically the predictive value of
Topo-I gene expression is still controversial (Vanhoefer et al,
2001). A positive relation between TS and Topo-I mRNA
expression was observed in colorectal cancer tissue (Ichikawa
et al, 1999). The response rates to CPT-11 alone had been reported
to be 43 and 15% in tumours with high and low TS expression,
respectively, among a group of colorectal cancer patients that did
not respond to 5-FU (Danenberg, 2003). The relationship between
TS and Topo-I mRNA expression in gastric cancer is unclear and
further studies are necessary to define the molecular mechanisms
underlying the regulation of these genes in gastric cancer.
Intratumoural DPD expression inversely correlates with the
sensitivity to 5-FU (Ishikawa et al, 1999; Nozawa et al, 2002) in
gastric cancer. However, our data indicated that the antitumour
effect of S-1 for gastric cancer was not influenced by intratumour
DPD gene expression, regardless of the combination of CPT-11.
This difference was explained by the inhibition of intratumoural
DPD by CDHP, which is contained in S-1 (Takechi et al, 2002).
There were no correlations between the antitumour activity of S-1
and DPD activity in human gastric xenografts (Fujiwara et al,
2003). Miyamoto et al. also reported that patients with positive
DPD showed a slightly higher response rate and longer survival
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Figure 2 Cumulative survival curves (Kaplan–Meier) when treated with
S-1 alone.
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Figure 3 DPD and TS mRNA in 26 primary gastric cancer treated with
S-1þCPT-11 in relation to nonresponse or response. There was no
statistical difference in DPD gene expression among responding and
nonresponding tumours. Median values of TS mRNA expression in
responding and nonresponding tumours were 4.26 and 2.11, respectively,
with a trend in favour of a higher TS mRNA expression for responding
tumours (P¼0.055; Mann–Whitney U test).
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Figure 4 Cumulative survival curves (Kaplan–Meier) when treated with
S-1 combined with CPT-11 in patients.
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lthan those with negative DPD, but without statistical significance,
when DPD expression was evaluated by immunohistochemical
methods using antirecombinant human polyclonal antibody
(Miyamoto et al, 2000). S-1 is thought to have antitumour activity
even in highly DPD expressed tumour, which is essentially
resistant to fluoropyrimidine without DPD inhibitor (Salonga
et al, 2000; Ichikawa et al, 2003).
TS and DPD gene expressions in primary gastric cancer differed
according to degree of differentiation (Ichikawa et al, in press). TS
gene expression was statistically higher in intestinal type than
diffuse type in 78 gastric cancer tissues, whereas DPD gene
expression of diffuse type was statistically higher than that of
intestinal type. The same results were obtained in this study cohort
including 53 gastric cancer tissues (data not shown). In a phase II
study of S-1 for metastatic gastric cancer, the response rate of the
diffuse type was higher than that for the intestinal type (Koizumi
et al, 2000). A higher response rate of S-1 for diffuse type might be
explained by both low TS expression and the inhibition of high
DPD by CDHP (Takechi et al, 2002; Fujiwara et al, 2003). Because
this study involved only a small number of patients, we could not
evaluate the predictive values of histological type when combined
with TS and DPD gene expression.
In this study, the S-1 combined with CPT-11 achieved the high
response rate of 50.0%, in comparison to the response rate of
29.6% in the S-1-alone regimen. However, median survival times
were 6.3 months in both regimens. In the randomised phase III
trial in patients with metastatic gastric cancer, the median survival
times ranged from 7.1 to 7.3 months, although the response rates
were statistically significant; 11% for the 5-FU-alone regimen and
34% for 5-FU combined with CDDP (Ohtsu et al, 2003). Thus, it is
not surprising that a higher response rate was not related with
longer survival time in the chemotherapy for gastric cancer (Ajani,
2000). Another possible explanation is the difference of second-
line treatment regimens (Table 1). Interestingly, in patients with
low TS expressed tumors, the response rate and survival for S-1
combined with CPT-11 were both worse than for the S-1-alone
regimen (response rate and median survival time; 38% and 6.6
months for S-1 combined with CPT-11 and 50% and 9.3 months
for S-1 alone). This might be explained by the decreased dose
intensity of S-1 in the S-1 combined with CPT-11 regimen,
compared with the S-1-alone regimens. In the S-1 combined with
CPT-11 regimens, S-1 is given for 2 weeks with 2 weeks’ rest,
although in the S-1-alone regimen there is consecutive adminis-
tration for 4 weeks followed by 2 weeks of no drug administration.
In conclusion, treatment effect of S-1 for gastric cancer
determined by the status of TS gene expression, regardless of that
of DPD gene expression. When CPT-11 combined with S-1,
intratumour TS gene expression did not predict antitumour effect.
However, these conclusions have been drawn from a limited
retrospective study of a relatively small number of patients.
Prospectively, randomised, translational treatment trials are
needed to corroborate our results.
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